Loading stock data…
Zenas BioPharma (ZBIO)
$25.55-0.32 (-1.24%)
Market ClosedLast close Jun 29
Zenas BioPharma, Inc., a clinical-stage biopharma company, engages in the development and commercialization of transformative immunology-based therapies.
Historical Price
Price (Candle)
50-Day SMA
200-Day SMA
Whystock Brain
The Narrative
Zenas BioPharma, Inc. in the Healthcare sector is trading at $25.55 with a market capitalization of $1.1B. Wall Street consensus targets $42.12 (8 analysts), implying a +64.9% move over the next 12 months. The stock is currently 43% below its 52-week high of $44.60, remaining 3.1% above its 200-day moving average. On fundamentals, Piotroski 2/9 flags weak fundamentals, Altman Z in the distress zone. The Whystock Score of 70/100 reflects bullish alignment across trend, valuation and analyst targets.
Ecosystem Influences
Sell-side targets imply +64.9% upside over 12 months
Long-term trend bullish (price vs 200-day SMA)
Macro-economic sensitivity to interest rate and inflation shifts
Quarterly Financials
| Metric (USD) | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 |
|---|---|---|---|---|---|
| Total Revenue | $0 | $0 | $0 | $0↓ | $10.00M |
| Gross Profit | — | — | — | — | — |
| Operating Income | -$77.35M↓ | -$71.31M↓ | -$47.58M↑ | -$55.16M↓ | -$37.33M |
| Net Income | -$80.99M↑ | -$240.44M↓ | -$51.50M↑ | -$52.22M↓ | -$33.57M |
Peer Comparison
JNJUNHPFE
Fundamentals
Zenas BioPharma, Inc., a clinical-stage biopharma company, engages in the development and commercialization of transformative immunology-based therapies. Its lead product candidate is obexelimab, a bifunctional monoclonal antibody designed to bind CD...
Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
$1.13B
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
-
Beta
High-beta play. Expect amplified moves vs. the broad market.
-
Div Yield
Low to zero yield. Return is entirely dependent on price appreciation.
0.00%
ROE
Average efficiency. Growth may require heavy reinvestment.
-126.60%
Volume
Today's trading volume
1.23M
Recent News
Zenas BioPharma's CEO Purchased 60,000 Company Shares. Here's a Deeper Look at the Transaction.
This clinical-stage biotech focused on immunology therapies reported a notable insider buy amid a year of strong stock performance.
Exchange-Traded Funds, Equity Futures Mixed Pre-Bell Wednesday Amid Fresh Economic Signals
The broad market exchange-traded fund SPDR S&P 500 ETF Trust (SPY) was down 0.2% and the actively tr
A Look At Zenas BioPharma (ZBIO) Valuation After Strong 1-Year Return And Recent Share Price Weakness
Recent trading performance and what it means for Zenas BioPharma (ZBIO) Zenas BioPharma (ZBIO) has drawn attention after a period of mixed trading. The stock is down 5% over the past month and about 27% over the past 3 months, yet it shows a 1-year total return above 80%. See our latest analysis for Zenas BioPharma. That mix of a strong 1 year total shareholder return of 82.9% alongside a share price that has fallen 26.9% over the past 3 months, with the latest close at $18.40, suggests...
Insiders Buy the Dip in These 2 Crushed Stocks With Strong Buy Ratings
The oldest rule in investing is simple – buy low and sell high. The challenge, of course, is figuring out which beaten-down stocks are genuinely broken and which ones are simply going through a rough patch.End of Quarter Sale - 70% Off Unlock powerful investing tools and data-driven insights with TipRanks Premium for more confident investment decisions. Discover top stock picks and new investment opportunities through TipRanks' Smart Investor Newsletter. That’s where a few reliable signals can h
Why Zenas BioPharma (ZBIO) Is Down 7.7% After Reporting a Sharply Wider Quarterly Net Loss
Zenas BioPharma, Inc. has reported first-quarter 2026 results, recording a net loss of US$80.99 million, compared with US$33.57 million a year earlier, with basic and diluted loss per share from continuing operations rising to US$1.46 from US$0.80. The widening loss underscores how the company’s cost base or investment spend has grown materially year on year, even as it remains in a loss-making phase. We will now examine how this sharp year-on-year increase in net loss shapes Zenas...